USD 16.69 Billion
Liver Cirrhosis Treatment Market Size, Share, Growth Analysis, By Treatment Modality(Antiviral, Vaccines, Chemotherapy, Immunosuppressive Agents), By Disease(Hepatitis, Non-alcoholic Fatty Liver Disease, Alcohol-induced, and Liver Cancer), By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35A2887 |
Region:
Global |
Published Date: May, 2024
Pages:
218
|Tables:
66
|Figures:
74
Liver Cirrhosis Treatment Market Insights
Liver Cirrhosis Treatment Market size was valued at USD 17.76 Billion in 2023 and is poised to grow from USD 18.9 Billion in 2024 to USD 31.09 Billion by 2032, growing at a CAGR of 6.42% during the forecast period (2025-2032).
Cirrhosis of the liver is a disease characterized by severe liver damage and scarring, leading to liver failure. Major pharmaceutical companies are doing a lot of research to develop new drugs for liver disease. Rapid lifestyle changes increase the risk of liver disease in humans. In addition, people with hepatitis, cystic fibrosis, syphilis, alpha-1 antitrypsin deficiency, alcohol abuse, and other liver diseases are at increased risk of developing cirrhosis of the liver, 887,000 people (about half the population of Idaho) died from hepatitis B. Most of these deaths were from to the fact that these patients had hepatitis B with liver cirrhosis and hepatocellular carcinoma (mainly cancer of the liver).
Key trends likely to drive the growth of the global liver cirrhosis treatment market include population of liver disease, increasing alcohol consumption and poor diet, according to a research study published in Clinical Liver Disease in June 2021. Chronic liver disease affecting about 1.5 billion people worldwide (CLD) is one of the leading causes of death and morbidity worldwide. Moreover, the most common cause of disease is liver non-alcoholic disease (NAFLD) (59%), followed by hepatitis B (2013), according to a June 2021 publication by the American Association for the Study of Liver Diseases. 29%), had hepatitis C (9%), and alcoholic liver disease (ALD) (2%). Furthermore, according to a study published in Clinical and Molecular Hepatology in October 2022, the prevalence of non-alcoholic fatty liver disease (NAFLD) is predicted to be 55.7% by 2040, worldwide therefore liver increasing infections helped to penetrate all markets.
Market snapshot - 2025-2032
Global Market Size
Largest Segment
Antiviral
Fastest Growth
Vaccines
Growth Rate
6.42% CAGR
Global Liver Cirrhosis Treatment Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Liver Cirrhosis Treatment Market Segmental Analysis
By treatment modality the market is segmented as antiviral, vaccines, chemotherapy, immunosuppressive agents, corticosteroids. By disease type the market is segmented as hepatitis, non-alcoholic fatty liver disease, alcohol-induced, liver cancer. The study provides market insights into North America, Europe, Asia-Pacific, Latin America, The Middle East and Africa.
Analysis by Treatment Modality
The antiviral segment accounted for the most important share of the liver disorder remedy marketplace in 2022 and the domination of the section is predicted to keep at some stage in the forecast period. The growing incidence of viral hepatitis infections, increasing wide variety of advancements in antiviral treatment plans, rising focus and screening applications for hepatitis B and C and developing emphasis on accomplishing viral suppression and stopping disorder progression commonly force the segmental growth.
The vaccines section had a great share of the worldwide market in 2022 and is expected to grow at a superb proportion of the global marketplace throughout the forecast duration. The developing emphasis on preventive healthcare, growing variety of government immunization packages, growing vaccination efforts for hepatitis B and growing awareness of the importance of vaccination against hepatitis viruses majorly propel the segmental growth.
Analysis by Disease
The liver cancer section is expected to account for the largest proportion of the worldwide marketplace in the course of the forecast period. The growing incidence of liver most cancers is one of the key elements propelling segmental growth. The developing occurrence of chance factors like viral hepatitis, alcohol abuse, and non-alcoholic fatty liver disorder, the growing quantity of advances in early detection and analysis of liver most cancers and growing treatment alternatives, including surgical treatment, chemotherapy, targeted cures, and immunotherapy further raise the growth charge of the segment.
The non-alcoholic fatty liver disease (NAFLD) phase is predicted to maintain a large share of the global marketplace throughout the forecast period. Factors which include the developing incidence of weight problems and metabolic syndrome, rising occurrence of NAFLD resulting from lifestyle adjustments, growing consciousness and prognosis of NAFLD and developing attention on way of life adjustments and pharmacological interventions pressure the segmental growth.
Global Liver Cirrhosis Treatment Market By Treatment Modality (%)
To get detailed analysis on other segments, Request For Free Sample Report
Liver Cirrhosis Treatment Market Regional Insights
The largest regional market. cirrhosis of the liver is common in the United States. In the U.S. saw 88,000 deaths from alcohol-related liver disease and hepatitis. Additionally, the health care system in the U.S. has 88,000 deaths from alcohol-related liver disease is also growing, contributing to the growth of the global liver cirrhosis treatment market. Furthermore, Pfizer Inc. has a strong presence in the market.
Asia Pacific has seen an increase in the incidence of cirrhosis of the liver. In addition, government and NGOs are developing hepatitis awareness programs which are expected to boost the global liver cirrhosis treatment market. Furthermore, the elderly population is more prone to various liver diseases, is increasing in countries such as India, Japan and China, positively impacting the market growth of liver disease treatment It is estimated, by 2050, one in four people in Asia and the Pacific will be 60 years old or older.
Global Liver Cirrhosis Treatment Market By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Liver Cirrhosis Treatment Market Dynamics
Drivers
Increased Incidence of Liver Disease
- Liver disease is still very common worldwide. Due to sedentary lifestyle, inactivity and especially poor diet, many people are suffering from liver disease. The aging population is getting older, and autoimmune diseases such as hepatitis and non-alcoholic fatty liver are on the rise. We can also attribute the significant increase in cases to alcohol consumption greater than. Increasing availability of therapies for liver diseases will drive the global market for treatment of liver diseases. In response to increased demand for hepatitis treatment, healthcare organizations funded the development of new drugs, devices, and treatment options, supported by biotechnology and research institutes around the world greatly led to the development of new drugs for the treatment of liver disease. Due to the growth and development, the market for treatment of liver diseases will be highly competitive and prosperous. This is expected to open lucrative opportunities for market participants and accelerate market growth.
Technological Advancements
- Technological advances in the diagnosis of liver diseases including imaging modalities, liver function tests and diagnostic biomarkers are fueling the market growth. These technological advances have enabled early detection of liver diseases and improved research accuracy. Other treatment options such as antibiotics, immunosuppressants, targeted therapies, and liver transplantation techniques may lead to liver diseases effective and diverse treatments, leading to market growth.
Restraints
Increased Costs
- High cost of drugs, procedures and surgeries required to treat liver disease significantly slows down market expansion. Inadequate health care, especially in rural or underserved areas, lack of understanding of liver diseases and their symptoms among the public and health professionals, and stigma associated with specific liver diseases, such as liver disease bacterial infections or liver diseases caused by alcohol. Difficulty in liver transplantation, stringent restrictions, and lack of effective liver disease drugs in R&D hamper the market growth Liver diseases and related diseases demand a lot of money has been spent on treatment.
High Cost of Treatment
- Cirrhosis, cirrhotic complications, and comorbidities add to the burden of chronic disease. Using the latest technologies and advancements, market participants can improve the efficacy and safety of these drugs. However, the cost of this technology and the process of developing new drugs are high. Expensive regulatory approvals and numerous drug tests also add to the cost. Thus, the high cost of treatment of liver diseases would drive the market growth.
Request Free Customization of this report to help us to meet your business objectives.
Liver Cirrhosis Treatment Market Competitive Landscape
The competitive environment of the Global Liver Cirrhosis Treatment Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. The liver cirrhosis treatment market is fragmented, with several key players. In terms of market share, the market is currently dominated by a few major players. The companies currently dominating the market include Abbott Laboratories, Gilead Sciences, Novartis AG, Sanofi, Astellas Pharma, Inc. and others.
Top Player’s Company Profiles
- Pfizer, Inc.
- Merck & Co., Inc.
- Novartis AG
- Takeda Pharmaceuticals Company Ltd.
- Zydus Pharmaceuticals, Inc.
- Gilead Science, Inc.
- Sanofi S.A.
- AstraZeneca plc
- GSK plc
- AbbVie Inc.
- Abbott Laboratories
- Astellas Pharma Inc.
- Bristol Myers Squibb
- Eli Lilly and Company
- F. Hoffman-LA Roche
- Emergent BioSolutions (Cangene bioPharma)
- Gilead Sciences, Inc.,
- Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
- Viatris Inc.
Recent Developments
- On January 31, 2022, Madrigal Pharmaceuticals saw an increase in premarket activity as the company delivered encouraging top-line data from the resmetirom study in non-alcoholic fatty liver disease.
- On September 30, 2021, Livmarly, Mirum’s minimally absorbed ileal bile acid transport (iBAT) inhibitor, received FDA approval. Emerging antibiotics are the first-line treatment for the disease, which affects 2,000–2,500 young people in the United States.
- January 2023: Takeda and Arrowhead Pharmaceuticals Inc. announced superior results of the Phase 2 SEQUOIA clinical trial of investigational fajirsiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease (AATD-LD).
Liver Cirrhosis Treatment Key Market Trends
- Rising Research and Development Efforts: Increasing R&D efforts to develop new therapies and therapeutic targets for liver disease, increasing services and funding for prevention, diagnosis and treatment of liver disease, increasing liver disease awareness, if needed the need for early diagnosis and healthcare costs. Increasing aging population, increasing awareness, improving healthcare infrastructure, increasing disposable income in emerging markets and increasing advancement in surgical procedures, procedures not taken more penetration and radiology interventions further support the growth of the market.
Liver Cirrhosis Treatment Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
The market is expanding due to changing eating habits and sedentary lifestyles. Furthermore, the market is expected to grow owing to increasing incidence of fatty liver disease caused by excessive fat, obesity, hypertension and diabetes Apart from this, many technological advancements such as liver bioartificial is driving the rapid expansion of the market. It is commonly used for individuals with severe liver disease and replaces liver function with liver cell regeneration. Accordingly, rapid antiviral drug acceptance, safety and efficacy, ability to inhibit hepatitis B virus and reduce the risk of tumors and hepatocellular carcinoma are driving the market growth positive influence.
| Report Metric | Details |
|---|---|
| Market size value in 2023 | USD 17.76 Billion |
| Market size value in 2032 | USD 31.09 Billion |
| Growth Rate | 6.42% |
| Base year | 2024 |
| Forecast period | 2025-2032 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Liver Cirrhosis Treatment Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Liver Cirrhosis Treatment Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Liver Cirrhosis Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Liver Cirrhosis Treatment Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Liver Cirrhosis Treatment Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Liver Cirrhosis Treatment Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
